Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis

被引：22
|
作者：
Prieto-Perez, Rocio [1 ]
Llamas-Velasco, Mar [2 ]
Cabaleiro, Teresa [1 ,3 ]
Solano-Lopez, Guillermo [2 ]
Marquez, Beatriz [4 ]
Roman, Manuel [1 ]
Ochoa, Dolores [1 ]
Talegon, Maria [1 ]
Dauden, Esteban [2 ]
Abad-Santos, Francisco [1 ,3 ]
机构：
[1] UAM, Inst Invest Sanitaria Princesa IP, Inst Teofilo Hernando, Clin Pharmacol Serv,Hosp Univ Princesa, Madrid, Spain
[2] Hosp Univ Princesa, Inst Invest Sanitaria Princesa, Dermatol Serv, Madrid, Spain
[3] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[4] Hosp Univ Gregorio Maranon, Clin Biochem Serv, Madrid, Spain
来源：
PHARMACOGENOMICS | 2017年 / 18卷 / 02期
关键词：
pharmacogenetics; psoriasis; ustekinumab; GENOME-WIDE ASSOCIATION; FUNCTIONAL VARIANTS; SUSCEPTIBILITY LOCI; CLINICAL-RESPONSE; CROHNS-DISEASE; POLYMORPHISMS; GENE; THERAPY; EFFICACY; DELETION;
D O I：
10.2217/pgs-2016-0122
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69). Results/Conclusion: The adjusted results (false discovery rate) showed an association between five SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33 and IL13 genes, and poor response to ustekinumab. Furthermore, six SNPs in CHUK, C17orf51, ZNF816A, STAT4, SLC22A4 and Corf72 genes were associated with better response to ustekinumab. However, there was no significant association between response to ustekinumab and SNPs in HLA-C as it has been recently described. Finally, a higher weight was obtained in nonresponders than responders (p = 0.018). Further studies would be necessary to be closer to personalized medicine.
引用
下载
收藏
页码：157 / 164
页数：8
相关论文
共 50 条
  • [1] Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis
    Dauden, E.
    Prieto-Perez, R.
    Llamas-Velasco, M.
    Cabaleiro, T.
    Abad-Santos, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S188 - S188
  • [2] Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis
    Fioranelli, Massimo
    Roccia, Maria Grazia
    Lotti, Torello
    DERMATOLOGIC THERAPY, 2017, 30 (05)
  • [3] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    Papp, Kim A.
    Blauvelt, Andrew
    Bukhalo, Michael
    Gooderham, Melinda
    Krueger, James
    Lacour, Jean-Philippe
    Menter, Alan
    Philipp, Sandra
    Sofen, Howard
    Tyring, Stephen
    Berner, Beate R.
    Visvanathan, Sudha
    Pamulapati, Chandrasena
    Bennett, Nathan
    Flack, Mary
    Scholl, Paul
    Padula, Steven J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16): : 1551 - 1560
  • [4] Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1456 - 1465
  • [5] Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis
    María C. Ovejero-Benito
    Ester Muñoz-Aceituno
    Alejandra Reolid
    Miriam Saiz-Rodríguez
    Francisco Abad-Santos
    Esteban Daudén
    American Journal of Clinical Dermatology, 2018, 19 : 209 - 222
  • [6] Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis
    Ovejero-Benito, Maria C.
    Munoz-Aceituno, Ester
    Reolid, Alejandra
    Saiz-Rodriguez, Miriam
    Abad-Santos, Francisco
    Dauden, Esteban
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (02) : 209 - 222
  • [7] Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
    Jo Lambert
    Jes Birger Hansen
    Anne Sohrt
    Luis Puig
    Dermatology and Therapy, 2021, 11 : 1265 - 1275
  • [8] Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis
    Yamauchi, Paul
    Elewski, Boni
    Wu, Jashin J.
    Rastogi, Shipra
    Israel, Robert J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB119 - AB119
  • [9] Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
    Lambert, Jo
    Hansen, Jes Birger
    Sohrt, Anne
    Puig, Luis
    DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1265 - 1275
  • [10] Pharmacokinetics and immunogenicity of the ustekinumab biosimilar candidate ABP 654 in patients with moderate-to-severe plaque psoriasis
    Chow, V.
    Mytych, D. T.
    Blauvelt, A.
    Papp, K.
    Barragan, C.
    Yamauchi, P.
    Crowley, J.
    Franklin, J.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1932 - I1932
12345